Past obstetric history and risk of malignant breast neoplasms

Many studies indicate hormonal disorders as a crucial reason for breast pathology. They are also probably responsible for the development of benign neoplasms and play a role in the origin and development of breast carcinoma. Although the mammary gland is under the influence of many steroid and peptide hormones such as thyroid hormones, prolactin, growth hormone, glucocorticosteroids, it is estrogen that plays an important role in the development of breast cancer. The purpose of the study was to analyze the obstetrical past of patients and the potential influence on the risk of developing malignant breast neoplasms. The participants in the study were healthy women with no changes in mammary glands (control group) and women with diagnosed malignant or benign breast neoplasms (study group). The total number of participants was 555 females aged 35-70 years. The study was carried out in the Greater Poland and Lubuskie province between 2005 and 2006. Hormonal disorders in childhood and puberty symptoms of early menarche play a crucial role in increasing the risk of malignant breast neoplasms. In women who experienced one or more miscarriages the risk of malignant breast neoplasms is significantly increased. On the basis of our study we calculated the odds ratio (OR) of malignant breast neoplasms among women who during lactation experienced problems needing medical intervention (OR = 2.25; 95% Cl, 1.20-4.19) in comparison to women who experienced no problems).

Breast cancer; Risk factors

[1] Jokiel M., Bielska-Lasota M., Kraszewska E.: “Poinformowanie i zachowania zdrowotne kobiet dotycza˛ce profilaktyki raka piersi wlatach 1998-2002”. Przeg. Epid., 2003, 57, 521.

[2] Stojgniew J. Sitko, Hetnal M.: “Determinanty systemowe profilaktykii leczenia raka sutka w Polsce”. Piele˛. Pol., 2001, 1, 68.

[3] Jassem J. Rak sutka: “Podre˛cznik dla studentów i lekarzy”. Springer PWN, Warszawa, 1998.

[4] Bin´kowska M.: “Hormonalna terapia a nowotwory. w: Hormonalna terapia zaste˛pcza. Pod red. Skalba P. Wyd. 2 uakt. i uzup”. PZWL, Warszawa, 2005, 348.

[5] Kocialkowski K., Otworowski A.: “Czynniki zagroz·enia (ryzyka)w raku sutka”. Ginek. Pol., 1993, 64, 36.

[6] Niwin´ska A.: “Hormonalne uwarunkowania raka sutka”. Ginek. Pol., 1997, 68, 558.

[7] Warenik-Szymankiewicz A., Me˛czekalski B.: “Hormonalna terapia zaste˛pcza a ryzyko rozwoju choroby nowotworowej”. Klin. Perinatol. Ginek., 1996, 16, 81.

[8] Czekanowski R.: “Choroby gruczolu sutkowego. Menopauza. Hormonalna terapia zaste˛pcza”. Warszawa: Wydawnictwo Medyczne Borgis 2003, 12.

[9] Budner M., Przybylski M.: “Diagnostyka i wczesne wykrywanie raka piersi. W: Poste˛py w ginekologii i poloz·nictwie”. Red. Spaczyn´ski M., XXIX Kongres Polskiego Towarzystwa Ginekologicznego, Poznan´ 2006, 87.

[10] Dworniak T.: “Rak sutka-profilaktyka”. Nowa Klinika., 2003, 10, 535.

[11] Godlewski D.: “Rak piersi w aspekcie medycznym i spolecznym”. Poznan´, 1997, 6.

[12] Tavani A., Gallus S., La-Vecchia C. i inni: “Risk factors for breast cancer in woman under 40 years”. Eur. J. Cancer, 1999, 35, 1361.

[13] Albanes D., Blair A., Taylor P.: “Physical activity and risk of cancer in the NHANES I population”. Am. J. Public. Health,1989, 79, 744.

[14] Ballad-Barbash R., Swanson Ch.A.: “Body weight estimation of risk for breast cancer and endometrial cancer”. Am. J. Clin. Nutr., 1996, 63, 4375.

[15] Chen W.Y., Manson J.E., Hankinson S.E., Rosner B., Holmes M.D., Wiilett W.C., Colditz G.A.: “Unopposed estrogen therapy and the risk of invasive breast cancer”. Arch. Intern. Med., 2006, 166, 1027.

[16] Costantino J., Gail M., Pee D., i inni: “Validation studies for models projecting the risk of invasive and total breast cancer incidence”. Nat. Cancer Inst., 1999, 91, 1541.

[17] Vogel V.: “Breast cancer prevention: a review of current evidence”. CA Cancer J. Clin., 2000, 50, 156.

[18] Mazurkiewicz M.: “Profilaktyka i metody wczesnego rozpoznania raka gruczolu piersiowego”. Med. Rodz., 2000, 10, 29.

[19] Zadroz·ny M.: “Poste˛powanie w zlos´liwych i lagodnych schorzeniach sutka. Diagnostyka i terapia wieku menopauzalnego”. Pod red. Pertyn´ski T. Wroclaw. Urban & Partner, 2004.

[20] Ostrowska L., Czapska D., Karczewski J.: “Otylos´c´ jako czynnik ryzyka nowotworu sutka u kobiet”. Polski Merkuriusz Lekarski, 2003, 81, 224.

[21] Becher H., Schmidt S., Chang-Claude J.: “Reproductive factors and familial predisposition for breast cancer by age 50 years. A case-control-family study for assessing main effects and possible gene-environment interaction”. Int. J. Epidemiol., 2003, 32, 38.

[22] Kamarudin R., Shah S.A., Hidayah N.: “Lifestyle factors and breast cancer: a case-control in Kuala Lumpur, Malaysia”. Asian. Pac. J. Cancer Prev., 2006, 7, 51.

[23] Lee S.Y., Kim M.T. Song M.S., Yoon S.J.: “Effect of lifetime lactation on breast cancer risk: a Korean women's cohort study”. Int. J. Cancer, 2003, 105, 390.

[24] Tessaro S., Beria J.U., Tomasi E., Victoria C.G.: “Breastfeeding and breast cancer: a case-control study in Southern Brazil”. Cad. Saude Publica, 2003, 19, 1593.

[25] Jernstrom H., Lubin´ski J., Lynch H.T., Ghadirian P., Neuhausen S., Isaacs C. et al.: “Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers”. J. Natl. Cancer Inst., 2004, 96, 1094.